David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy

episode

CME in Minutes: Education in Dermatology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Stalingrad Of The Adriatic: The Sangro (Part 1) 52 min · 23 Sep 2026 · WW2 Pod: We Have Ways of Making You Talk

7PM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

Richard’s Top 3 Music Videos Of All Time 35 min · 23 Sep 2026 · The Rest Is Entertainment

Ant Forgets Dec’s Birthday 🎂😬 57 min · 23 Sep 2026 · Hanging Out With Ant & Dec

Would Sam & Pete Betray Each Other on Celebrity Traitors?! 37 min · 23 Sep 2026 · Staying Relevant

Rights for the Unborn: How Should We Protect Future Generations? (Sophie Howe) 45 min · 23 Sep 2026 · Radical

Report any issue

Source

Recorded03 Jan 2024

Publisherc.answersincme.com ↗

Handlerec:1447300

Show notes

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in